Evaluating Proactive Outreach for Prior Authorization Recertifications in Medicaid Patients

被引:0
|
作者
Vishwanath, Soumya [1 ]
Tran, Stephanie N. [1 ]
Pomfret, Thomas C. [1 ]
Boss, Kaelyn C. [1 ]
Tesell, Mark [1 ]
Price, Mylissa [1 ]
Alper, Caroline J. [1 ]
Muchnik, Lorean [1 ]
Clements, Karen M. [1 ]
Lenz, Kimberly [2 ]
机构
[1] UMass Chan Med Sch Commonwealth Med, 333 South St, Shrewsbury, MA 01545 USA
[2] MassHealth, Off Clin Affairs, Quincy, MA USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2021年 / 27卷 / 11期
关键词
D O I
10.37765/ajmc.2021.88783
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
OBJECTIVES: To assess the effectiveness of a proactive provider intervention in prompting prior authorization (PA) submissions or provider response prior to PA expiration for medically complex Medicaid patients. STUDY DESIGN: Pre-post outreach study with data from pharmacy claims and provider outreach. METHODS: The intervention and historical comparison (control) groups included expired PAs from December 2019 to February 2020 and from December 2018 to February 2019, respectively. Provider outreach, including telephonic and fax attempts, was conducted over a 2-week period prior to PA expiration. Outcomes were classified as positive or negative based on provider conversation coupled with the result (eg, PA submission) for the intervention group and based solely on pharmacy claims for the control group. The primary end point was the percentage of positive outcomes between the groups, analyzed via chi(2) test. The time from PA expiration to the new PA submission was evaluated via t test. RESULTS: A total of 342 outreach attempts were conducted for 270 PAs representing 193 unique patients. Outreach was more likely to result in positive outcomes in the intervention group vs no outreach in the control group (87% vs 25%; P < .00001). On average, PAs were submitted 3.5 days prior to expiration in the intervention group vs 13.0 days after expiration in the control group (t = -7.50; P < .00001). CONCLUSIONS: Proactive outreach resulted in a greater percentage of PA submissions and a significantly reduced time to PA submission. These findings provide important information for payers in guiding clinical programs to enhance continuity of care among at-risk populations.
引用
收藏
页码:E395 / E399
页数:5
相关论文
共 50 条
  • [21] ASSESSING THE IMPACT OF A MEDICAID PRIOR AUTHORIZATION (PA) POLICY FOR DULOXETINE ON ANTIPSYCHOTIC USE AMONG PATIENTS WITH DEPRESSION
    Birnbaum, H. G.
    Ivanova, J. I.
    Waldman, T.
    Swallow, E.
    Cummings, A. K.
    Clark, T.
    Peng, X.
    Swindle, R.
    VALUE IN HEALTH, 2013, 16 (03) : A68 - A69
  • [22] Clinical and financial outcomes of a medicaid proton pump inhibitor prior authorization program
    Mager, DT
    Motheral, BR
    AMERICAN JOURNAL OF MANAGED CARE, 2004, 10 (09): : 649 - 649
  • [23] The Consequences of Removing Prior Authorization for Buprenorphine in Medicaid-Building an Evidence Base
    Allen, Lindsay
    Burns, Marguerite
    Saloner, Brendan
    JAMA HEALTH FORUM, 2022, 3 (06):
  • [24] Unintended Impacts of a Medicaid Prior Authorization Policy on Access to Medications for Bipolar Illness
    Lu, Christine Y.
    Soumerai, Stephen B.
    Ross-Degnan, Dennis
    Zhang, Fang
    Adams, Alyce S.
    MEDICAL CARE, 2010, 48 (01) : 4 - 9
  • [25] Impact of medicaid prior authorization policies on use of angiotensin receptor blockers.
    Fischer, M. A.
    Choudhry, N. K.
    Winkelmayer, W. C.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 : 70 - 70
  • [26] Variability across US medicaid prior authorization programs for anti-depressants
    Polinski, Jennifer M.
    Wang, Philip
    Servi, Amber
    Robinson, Elizabeth
    Fischer, Michael
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S196 - S197
  • [27] Effects of prior authorization on statewide Medicaid non-stress testing claims
    Lowery, C
    Kay, H
    Norton, J
    Mcghee, J
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (06) : S160 - S160
  • [28] Examining the perceived burden of prior authorization of psychotherapeutics among Texas Medicaid prescribers
    Brown, C.
    Rascati, K. L.
    Nwokeji, E. D.
    Corbell, Z. D.
    Phillips, G. A.
    Zachry, W. M.
    VALUE IN HEALTH, 2008, 11 (03) : A134 - A134
  • [29] Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
    Christine, Paul J.
    Larochelle, Marc R.
    Lin, Lewei
    Mcbride, Jonathon
    Tipirneni, Renuka
    JAMA HEALTH FORUM, 2023, 4 (10): : E233549
  • [30] Impact of prior authorization on use of angiotensin receptor blockers in US medicaid programs
    Fischer, Michael A.
    Choudhry, Niteesh K.
    Winkelmayer, Wolfgang C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S45 - S45